Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study

Summary

This study is being carried out to see if adding ZD1839 to other standard supportive care is more effective than standard supportive care alone for the treatment of patients with NSCLC whose disease has recurred after previous chemotherapy treatment.

Timeline

Start

2003-07

Primary completion

—

Completion

2005-04

Drugs

Indications